In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Medifast Inc (NYSE: MED) closed at $25.18 down -5.66% from its previous closing price of $26.69. In other words, the price has decreased by -$5.66 from its previous closing price. On the day, 0.57 million shares were traded. MED stock price reached its highest trading level at $27.18 during the session, while it also had its lowest trading level at $24.98.
Ratios:
For a deeper understanding of Medifast Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.76 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.25. For the most recent quarter (mrq), Quick Ratio is recorded 2.25 and its Current Ratio is at 2.84. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on October 13, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $82.
On November 04, 2022, DA Davidson Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $278 to $106.
Jefferies Downgraded its Buy to Hold on August 04, 2022, whereas the target price for the stock was revised from $345 to $150.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 08 ’24 when SCHLACKMAN SCOTT sold 4,053 shares for $39.44 per share. The transaction valued at 159,866 led to the insider holds 7,785 shares of the business.
BROWN JEFFREY J bought 58 shares of MED for $4,020 on Nov 07 ’23. The Director now owns 5,784 shares after completing the transaction at $68.89 per share. On Nov 07 ’23, another insider, SCHLACKMAN SCOTT, who serves as the Director of the company, bought 53 shares for $68.89 each. As a result, the insider paid 3,627 and bolstered with 10,538 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MED now has a Market Capitalization of 291914272 and an Enterprise Value of 133447272. As of this moment, Medifast’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.06, and their Forward P/E ratio for the next fiscal year is 13.32. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.20. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.31 while its Price-to-Book (P/B) ratio in mrq is 1.31. Its current Enterprise Value per Revenue stands at 0.149 whereas that against EBITDA is 1.397.
Stock Price History:
Over the past 52 weeks, MED has reached a high of $109.52, while it has fallen to a 52-week low of $25.36. The 50-Day Moving Average of the stock is -28.06%, while the 200-Day Moving Average is calculated to be -60.09%.
Shares Statistics:
For the past three months, MED has traded an average of 440.98K shares per day and 605160 over the past ten days. A total of 10.90M shares are outstanding, with a floating share count of 10.65M. Insiders hold about 2.67% of the company’s shares, while institutions hold 94.64% stake in the company. Shares short for MED as of 1713139200 were 2989116 with a Short Ratio of 6.78, compared to 1710460800 on 2049519. Therefore, it implies a Short% of Shares Outstanding of 2989116 and a Short% of Float of 41.43.
Dividends & Splits
According to the company, the forward annual dividend rate for MED is 3.30, from 3.3 in the trailing year. Against a Trailing Annual Dividend Yield of 0.12364181The stock’s 5-year Average Dividend Yield is 4.78.
